Russell Clayton - Jan 17, 2024 Form 4 Insider Report for Larimar Therapeutics, Inc. (LRMR)

Role
Chief Medical Officer
Signature
/s/ Jennifer Johansson, Attorney-in-fact
Stock symbol
LRMR
Transactions as of
Jan 17, 2024
Transactions value $
$0
Form type
4
Date filed
1/19/2024, 04:31 PM
Previous filing
Jul 18, 2023

Transactions Table

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Ownership Footnotes
transaction LRMR Common Stock Award $0 +22.5K $0.00 22.5K Jan 17, 2024 Direct F1

Derivative Securities (e.g., puts, calls, warrants, options, convertible securities)

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Underlying Class Amount Exercise Price Ownership Footnotes
transaction LRMR Stock Option (Right to Buy) Award $0 +135K $0.00 135K Jan 17, 2024 Common Stock 135K $4.21 Direct F2
* An asterisk sign (*) next to the price indicates that the price is likely invalid.

Explanation of Responses:

Id Content
F1 Each share is represented by a restricted stock unit ("RSU"). Each RSU represents a contingent right to receive one share of the Issuer's Common Stock upon settlement.
F2 The option vests 25% on January 17, 2025, with the remaining 75% vesting in equal monthly installments on the last day of each of the 36 calendar months immediately following such date, subject to the Reporting Person's continued service with the Issuer through the applicable vesting date.